Solutions

• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • ScFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing
  • CAR Cell In Vitro Assay
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trial
  • One-Stop Canine CAR-T Therapy Development
  • One-Stop mRNA CAR-T Therapy Development
  • TRAC-CAR-T Cell Development
  • Modular CAR-T Cell Generation
  • One-Stop Silence™ CAR-T Cell Development
  • Vaccine Boosting CAR-T Cell Therapy
  • STAb-T Cell Therapy Development
  • CAR-T Therapy Development in the Non-Cancer Field
  • Anti-HIV CAR Cell Therapy Development
  • T Cell Activity Modulator Discovery
  • T Cell Programming
  • Virus Specific T Cell (VST) Development
  • Antibody-Coupled T Cell Receptor (ACTR) Development
  • Organoid-induced hPSC-original T Cell Differentiation
  • γδ T Cell Engineering
  • CAR-T CDMO
• One-Stop TCR-T Therapy Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Clinical Application
  • TCR Analysis
  • TCR Tetramerization Construction
  • ScFv-TCR T Cell Therapy Development
  • AbTCR Development
  • Bispecific TCR Development
  • CER Development
• One-Stop CAR-MA Therapy Development
• One-Stop CAR-NK Therapy Development
  • One-Stop CAR-NKT Therapy Development
  • One-Stop UniCAR-NK Therapy Development
  • iPSC-derived CAR-NK Therapy Development
  • One-Stop TCR-NK Therapy Development
  • NK Cell Genetic Engineering
  • NK Cell Expansion
• One-Stop CAR-B Therapy Development
• One-Stop CAR-Monocyte Therapy Development
• One-Stop Cytokine Release Syndrome (CRS) Management
• TCR-Like Antibody Development
  • MHC/Peptide Complex Production
  • TCR-Like Antibody Discovery
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction & Evaluation
• In Vivo Cell Engineering Development
  • In Vivo CAR-T Cell Engineering
  • In Vivo B Cell Engineering
  • In Vivo CAR-NK Cell Engineering
  • In Vivo CAR-M Cell Engineering
• One-Stop Allogeneic Cell Therapy Development
  • Allogeneic CAR-T Therapy Development
  • Allogeneic TCR-T Therapy Development
  • Allogeneic CAR-NK Therapy Development
  • Allogeneic CAR/TCR Cell Design & Engineering
  • Other Allogeneic Cell Therapy Development
• TCR/CAR/Antigen-Engineered Tregs Development
  • CAR-Treg Development
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing
  • Dendritic Cell Vaccine Development
• Immune Genotyping
  • HLA Typing
  • KIR Typing
  • HLA Testing
  • Dog DLA Genotyping
  • Guinea Pig GPLA Genotyping
  • Mouse H2 Genotyping
  • Rabbit RLA Genotyping
  • Rat RT1 Genotyping
  • Rhesus Macaque MHC Genotyping
• Other Services
  • Tumor-infiltrating Lymphocyte-based Antibody Discovery

CD34⁺ HSC Hu-NSG Mice Model Development Service

Online Inquiry

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

NSG engrafted with human CD34+ hematopoietic stem cells (HSC) can develop multi-lineage human immune cells, and is effective in vivo model for immunology or CAR-T therapy efficacy research and infectious disease research. The HuCD34-NSG mouse from Creative Biolabs is a research-ready mouse model with a human-like immune system created by adoptive transfer of CD34+ HSC cells. CD34+ mice are in our inventory and can be shipped to your institution immediately or for efficacy studies at our institution.

Brief Introduction

CD34+ humanized mouse is a model in which human umbilical cord blood and HSC are transplanted into NSG mice. After HSC transplantation, it can be colonized in mouse bone marrow and continuously produce various types of hematopoietic or immune cells, such as T cells, B cells, NK cells, myeloid cells, etc. Since its immune cells are developed in mice and are tolerant of mice, GvHD will not appear, making it an ideal choice for long-term research.

Key Features

• By running NHP toxicology and rodent studies in the same facility, time can be saved and logistics can be simplified.
• Reduce development time and improve cost-effectiveness through on-site pathology/histopathology services (including IHC, ICC and IF)
• Start research quickly to get reliable results quickly. The research can be started within 4 weeks, and the duration of the research can be optimized to suit the needs of customers and projects
• A cost-effective way to guide your GLP research. Our exploratory non-GLP toxicology screening usually only costs a small part of the cost of GLP research.

Hu-CD34 NSG Humanization Process

Female mice were injected with human hematopoietic stem cells (hu-CD34 +). Approximately 2 months after the injection, the implantation of mature human leukocytes (hCD45 +) was confirmed.

Fig.1 Engraftment of hematopoietic stem cells (HSCs) into NSG mice.

Hu-CD34 NSG & PDX Capabilities

Our NSG mouse models have a higher degree of immunodeficiency. It lacks NK cells while lacking T cells and B cells, and innate immunity is compromised. The NSG model is very suitable for human tumor cell transplantation (CDX), human tumor tissue transplantation (PDX) for immune reconstruction.

Highlights

• Convenient - HuCD34-NCG PDX mice can be used for research and can express human immune cells
• Consistent - every mouse has been tested for humanity
• Stable - the implantation of hematopoietic cells provides a research platform for further research
• License - free-no additional licensing fees or royalties

Fig.2 Establishment of Hu-CD34 NSG PDX model.

Applications

Hu-CD34-NSG is an ideal choice for long-term in vivo research in the field of immunology and cell therapy because they have a life span of more than 12 months after CD34+ implantation. Specifically, they can be used to evaluate the CAR-T therapies including but not limited to: monitor CAR-T distribution in vivo, determine CAR-T persistency, and monitor Cytokine Release Syndromes.

For more detailed information, please feel free to contact us or directly sent us an inquiry.